Literature DB >> 22399513

Phenotypical analysis of lymphocytes with suppressive and regulatory properties (Tregs) and NK cells in the papillary carcinoma of thyroid.

Foteini Gogali1, George Paterakis, George Z Rassidakis, Gregory Kaltsas, Chrysoula I Liakou, Panagiotis Gousis, Evangelos Neonakis, Menelaos N Manoussakis, Charis Liapi.   

Abstract

CONTEXT: The immune system seems to play a key role in preventing metastasis and recurrence of thyroid cancer. T regulatory lymphocytes (Tregs) and natural killer (NK) cells play an important role in the dysfunction of the host immune system in cancer patients.
OBJECTIVE: We investigated thyroid gland infiltration by Tregs and NK cells in patients with papillary thyroid cancer (PTC) and thyroid nodular goiter (TNG). The correlation between the extent of the disease and the lymphocytic infiltration of Tregs and NK cells was examined. DESIGN, SETTING, AND PARTICIPANTS: A total of 65 patients with PTC, 25 with TNG, and 50 healthy controls were studied. Blood and tissue samples from 28 patients with PTC and 13 with TNG and blood samples from the healthy controls were analyzed for T4 (CD3(+)CD4(+)), T8 (CD3(+)CD8(+)), NK (CD3(-)CD16(+)CD56(+)), and CD4(+)CD25(+)CD127(-/low) Tregs by flow cytometry (FC). Tissue samples were also analyzed for Foxp3(+) Tregs by immunohistochemistry.
RESULTS: Tregs showed greater infiltration in thyroid tissue of PTC patients compared with patients with TNG (P < 0.0009 for FC and P < 0.0001 for immunohistochemistry); FC analysis of blood samples showed no difference between the groups. Flow cytometry analysis showed significantly increased NK cells in PTC tissue compared with TNG tissue (P = 0.037), whereas blood samples showed no difference. CD4(+) and CD8(+) T cells did not differ in blood and tissue samples. Increased Tregs tissue infiltration was positively correlated with advanced disease stage (P < 0.0026), whereas NK infiltration was negatively correlated (P < 0.0041).
CONCLUSION: Tregs and NK cells may be important regulators of thyroid cancer progression.

Entities:  

Mesh:

Year:  2012        PMID: 22399513     DOI: 10.1210/jc.2011-1838

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

1.  BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Adrian J Correa; Jonathan S LoPresti; Alan L Epstein
Journal:  Thyroid       Date:  2014-07-15       Impact factor: 6.568

2.  Analysis of regulatory T cells frequency in peripheral blood and tumor tissues in papillary thyroid carcinoma with and without Hashimoto's thyroiditis.

Authors:  Y Liu; X Yun; M Gao; Y Yu; X Li
Journal:  Clin Transl Oncol       Date:  2014-11-12       Impact factor: 3.405

Review 3.  The immune network in thyroid cancer.

Authors:  Maria Rosaria Galdiero; Gilda Varricchi; Gianni Marone
Journal:  Oncoimmunology       Date:  2016-03-30       Impact factor: 8.110

4.  Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3+ T lymphocytes.

Authors:  T Pilli; P Toti; R Occhini; M G Castagna; S Cantara; M Caselli; S Cardinale; L Barbagli; F Pacini
Journal:  J Endocrinol Invest       Date:  2017-12-11       Impact factor: 4.256

5.  Mechanism of immune tolerance induced by donor derived immature dendritic cells in rat high-risk corneal transplantation.

Authors:  Xiao-Wei Gao; Yan Fu; Wen-Jing Li; An-Jie Du; Xia Li; Xu-Dong Zhao
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

6.  MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.

Authors:  Trevor E Angell; Melissa G Lechner; Julie K Jang; Jonathan S LoPresti; Alan L Epstein
Journal:  Clin Cancer Res       Date:  2014-10-07       Impact factor: 12.531

7.  T-Cell Lymphopenia in Patients with Advanced Thyroid Carcinoma Is Associated with Poor Prognosis.

Authors:  Katrin Rabold; Paul R Gielen; Esther D Kers-Rebel; Mihai G Netea; Jan W A Smit; Gosse J Adema; Romana T Netea-Maier
Journal:  Oncologist       Date:  2019-01-03

Review 8.  Immunotherapy for advanced thyroid cancers - rationale, current advances and future strategies.

Authors:  Jena D French
Journal:  Nat Rev Endocrinol       Date:  2020-08-24       Impact factor: 43.330

9.  Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter.

Authors:  Hang Yu; Xiaomei Huang; Xiaosun Liu; Hailong Jin; Ge'er Zhang; Qing Zhang; Jiren Yu
Journal:  Endocrine       Date:  2012-12-22       Impact factor: 3.633

10.  Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.

Authors:  Jill J Bastman; Hilary S Serracino; Yuwen Zhu; Michelle R Koenig; Valerica Mateescu; Sharon B Sams; Kurtis D Davies; Christopher D Raeburn; Robert C McIntyre; Bryan R Haugen; Jena D French
Journal:  J Clin Endocrinol Metab       Date:  2016-04-05       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.